| Budget Amount *help |
¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2012: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
|
|---|
| Research Abstract |
Small-molecule compounds that potently affect osteoclastogenesis or osteogenesis could form the basis for effective therapeutic strategies for alveolar bone regenerative medicine. In this study, we established osteoclast progenitor cell (NFAT/luciferase reporter cell)- or osteoblast (type I collagen/GFP reporter cell)-based high-throughput screening systems. These screening systems could identify candidates for osteoclastogenesis- or osteogenesis-targeting compounds in reliable manner, thus making it a promising tool for finding novel synthetic regulators of bone formation.
|
